To evaluate the effects of the selective JAK inhibitor tofacitinib in a patient with both rheumatoid arthritis (RA) and polycythemia vera (PV).
Key Findings:
Tofacitinib demonstrated significant rheumatologic efficacy in controlling RA symptoms.
Hematologic parameters related to PV remained stable, indicating limited impact on PV-related conditions.
The patient achieved clinical and ultrasonographic remission of RA within 3 months of tofacitinib initiation.
Interpretation:
Tofacitinib effectively manages RA symptoms while maintaining hematologic safety in patients with concurrent PV, highlighting the need for JAK2-specific therapies for PV.
Limitations:
Only a single case report, limiting generalizability.
No prior studies on the use of JAK inhibitors in patients with both RA and PV.
Conclusion:
Tofacitinib is effective for RA in patients with concomitant PV, but its limited effect on erythrocytosis suggests the necessity for targeted JAK2 therapies.
